BIESPECIFIC BINDING AGENTS EGFR AND c-MET, CONJUGATES THEREOF AND METHODS OF USE THEREOF
Patent Information
- Application Number
- ARP20250100545
- Authority / Receiving Office
- AR · AR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-27
- Filing Date
- 2025-02-27
- Publication Date
- 2026-09-02
Claims
The present invention provides bispecific EGFR and c-MET antibodies, antigen-binding portions thereof, other binding agents, and bispecific EGFR and c-MET conjugates thereof, as well as methods and uses of said antibodies and conjugates for the treatment of cancer and autoimmune diseases.
1. A bispecific binding agent comprising: a first binding domain that binds to EGFR; and a second domain that binds to c-MET, wherein the first binding domain comprises a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region (VH) and the light chain comprising a light chain variable region (VL), the VH region comprising the complementarity-determining regions HCDR1, HCDR2, and HCDR3 arranged in the framework regions of the heavy chain variable region, and the VL region comprising LCDR1, LCDR2, and LCDR3 arranged in the framework regions of the light chain variable region, wherein the HCDR1 of the first binding domain has an amino acid sequence of SEQ ID No. 139 or 174, the HCDR2 of the first binding domain has an amino acid sequence of SEQ ID No. 140 or 175, and the HCDR3 of the first binding domain has an amino acid sequence of SEQ ID No. 141 or 176,The LCDR1 of the first binding domain has an amino acid sequence from SEQ ID No. 142 or 177, the LCDR2 of the first binding domain has an amino acid sequence from DAS or KVS, and the LCDR3 of the first binding domain has an amino acid sequence from SEQ ID No. 143 or 178.
19. A pharmaceutical composition comprising the binding agent of any of claims 1 to 18 and a pharmaceutically acceptable carrier.
20. A nucleic acid encoding the binding agent of any of claims 1 to 18.
21. A vector comprising the nucleic acid of claim 20.
22. A cell line comprising the vector of claim 21 or the nucleic acid of claim 20.
23. A conjugate comprising: the bispecific linking agent of any of claims 1 to 18, at least one linker attached to the bispecific linking agent; at least one drug unit, wherein each drug unit is attached to a linker, wherein the linker optionally comprises at least one polar group.
59. A pharmaceutical composition comprising the conjugate of any of claims 23-58 and a pharmaceutically acceptable carrier.